Empagliflozin reduces myocardial ketone utilization while preserving glucose utilization in diabetic hypertensive heart disease: A hyperpolarized 13C magnetic resonance spectroscopy study

Diabetes, Obesity and Metabolism

Volumn 21, Issue 2, 2019, Pages 357-365

  Abdurrachim, Desiree ^a   Teo, Xing Qi ^a   Woo, Chern Chiuh ^a   Chan, Wei Xin ^a   Lalic, Janise ^a   Lam, Carolyn S P ^a,b   Lee, Philip Teck Hock ^a  

^a AGENCY FOR SCIENCE   (Singapore)

^b DEPARTMENT OF CARDIOLOGY   (Singapore)

Author keywords

animal pharmacology; cardiovascular disease; diabetes complications; empagliflozin; experimental pharmacology; glucose metabolism

Indexed keywords

3 HYDROXYBUTYRIC ACID; ACETOACETATE C 13; EMPAGLIFLOZIN; FATTY ACID; GLUCOSE; INSULIN; KETONE; PYRUVATE C 13; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG; BENZHYDRYL DERIVATIVE; GLUCOSIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARBON NUCLEAR MAGNETIC RESONANCE; CARDIAC IMAGING; CARDIOVASCULAR MAGNETIC RESONANCE; CONTROLLED STUDY; DIABETIC HYPERTENSION; DRUG EFFECT; FATTY ACID TRANSPORT; GLUCOSE BLOOD LEVEL; GLUCOSE UTILIZATION; HEART FAILURE; HEART FUNCTION; IN VIVO STUDY; KETOGENESIS; LIVER; MALE; NONHUMAN; OBESITY; PROTEIN EXPRESSION; RAT; SPONTANEOUSLY HYPERTENSIVE HEART FAILURE RAT; ANIMAL; BLOOD PRESSURE; BODY WEIGHT GAIN; CARDIAC MUSCLE; CHEMISTRY; COMPLICATION; DIABETIC ANGIOPATHY; DIAGNOSTIC IMAGING; EXPERIMENTAL DIABETES MELLITUS; HEART; METABOLISM; PATHOLOGY; PROCEDURES; SPONTANEOUSLY HYPERTENSIVE RAT; SPRAGUE DAWLEY RAT;

ANIMALS; BENZHYDRYL COMPOUNDS; BLOOD PRESSURE; CARBON-13 MAGNETIC RESONANCE SPECTROSCOPY; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC ANGIOPATHIES; GLUCOSE; GLUCOSIDES; HEART; KETONES; MALE; MYOCARDIUM; OBESITY; RATS; RATS, INBRED SHR; RATS, SPRAGUE-DAWLEY; WEIGHT GAIN;

EID: 85055144358     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/dom.13536     Document Type: Article

References (32)

1. Kannel WB, McGee DL. Diabetes and cardiovascular risk factors: the Framingham study. Circulation. 1979;59(1):8-13
2. Smith RJ, Goldfine AB, Hiatt WR. Evaluating the cardiovascular safety of new medications for type 2 diabetes: time to reassess? Diabetes Care. 2016;39(5):738-742. https://doi.org/10.2337/dc15-2237
3. Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117-2128. https://doi.org/10.1056/NEJMoa1504720
4. Lopaschuk GD, Ussher JR, Folmes CDL, Jaswal JS, Stanley WC. Myocardial fatty acid metabolism in health and disease. Physiol Rev. 2010;90(1):207-258. https://doi.org/10.1152/physrev.00015.2009
5. Glatz JFC, Bonen A, Ouwens DM, Luiken JJFP. Regulation of sarcolemmal transport of substrates in the healthy and diseased heart. Cardiovasc Drugs Ther. 2006;20(6):471-476. https://doi.org/10.1007/s10557-006-0582-8
6. Lopaschuk GD, Ussher JR. Evolving concepts of myocardial energy metabolism: more than just fats and carbohydrates. Circ Res. 2016;119(11):1173-1176. https://doi.org/10.1161/CIRCRESAHA.116.310078
7. Aubert G, Martin OJ, Horton JL, et al. The failing heart relies on ketone bodies as a fuel. Circulation. 2016;133(8):698-705. https://doi.org/10.1161/CIRCULATIONAHA.115.017355
8. Bedi KC, Snyder NW, Brandimarto J, et al. Evidence for intramyocardial disruption of lipid metabolism and increased myocardial ketone utilization in advanced human heart failure. Circulation. 2016;133(8):706-716. https://doi.org/10.1161/CIRCULATIONAHA.115.017545
9. Ferrannini E, Baldi S, Frascerra S, et al. Shift to fatty substrate utilization in response to sodium–glucose cotransporter 2 inhibition in subjects without diabetes and patients with type 2 diabetes. Diabetes. 2016;65(5):1190-1195
10. Ferrannini E, Mark M, Mayoux E. CV protection in the EMPA-REG OUTCOME trial: a thrifty substrate hypothesis. Diabetes Care. 2016;39(7):1108-1114. https://doi.org/10.2337/dc16-0330
11. Mudaliar S, Alloju S, Henry RR. Can a shift in fuel energetics explain the beneficial cardiorenal outcomes in the EMPA-REG OUTCOME study? A unifying hypothesis. Diabetes Care. 2016;39(7):1115-1122. https://doi.org/10.2337/dc16-0542
12. Lopaschuk GD, Verma S. Empagliflozin's fuel hypothesis: not so soon. Cell Metab. 2016;24(2):200-202. https://doi.org/10.1016/j.cmet.2016.07.018
13. Al Jobori H, Daniele G, Adams J, et al. Determinants of the increase in ketone concentration during SGLT2 inhibition in NGT, IFG and T2DM patients. Diabetes Obes Metab. 2017;19(6):809-813. https://doi.org/10.1111/dom.12881
14. Wentz AE, D'Avignon DA, Weber ML, et al. Adaptation of myocardial substrate metabolism to a ketogenic nutrient environment. J Biol Chem. 2010;285(32):24447-24456. https://doi.org/10.1074/jbc.M110.100651
15. Kolwicz SC, Airhart S, Tian R. Ketones step to the plate: a game changer for metabolic remodeling in heart failure? Circulation. 2016;133(8):689-691. https://doi.org/10.1161/CIRCULATIONAHA.116.021230
16. Taegtmeyer H. Failing heart and starving brain: ketone bodies to the rescue. Circulation. 2016;134(4):265-266. https://doi.org/10.1161/CIRCULATIONAHA.116.022141
17. Horton JL, Martin OJ, Lai L, et al. Mitochondrial protein hyperacetylation in the failing heart. JCI Insight. 2016;1(2):1-14. https://doi.org/10.1172/jci.insight.84897
18. Russell RR, Taegtmeyer H. Changes in citric acid cycle flux and anaplerosis antedate the functional decline in isolated rat hearts utilizing acetoacetate. J Clin Invest. 1991;87(2):384-390. https://doi.org/10.1172/JCI115008
19. Stanley WC, Meadows SR, Kivilo KM, Roth BA, Lopaschuk GD. Beta-hydroxybutyrate inhibits myocardial fatty acid oxidation in vivo independent of changes in malonyl-CoA content. Am J Physiol Heart Circ Physiol. 2003;285(4):H1626-H1631. https://doi.org/10.1152/ajpheart.00332.2003
20. Kolwicz SCJ, Olson DP, Marney LC, Garcia-Menendez L, Synovec RE, Tian R. Cardiac-specific deletion of acetyl CoA carboxylase 2 prevents metabolic remodeling during pressure-overload hypertrophy. Circ Res. 2012;111(6):728-738. https://doi.org/10.1161/CIRCRESAHA.112.268128
21. Abdurrachim D, Nabben M, Hoerr V, et al. Diabetic db/db mice do not develop heart failure upon pressure overload: a longitudinal in vivo PET, MRI, and MRS study on cardiac metabolic, structural, and functional adaptations. Cardiovasc Res. 2017;113(10):1148-1160. https://doi.org/10.1093/cvr/cvx100
22. Abdurrachim D, Luiken JJFP, Nicolay K, Glatz JFC, Prompers JJ, Nabben M. Good and bad consequences of altered fatty acid metabolism in heart failure: evidence from mouse models. Cardiovasc Res. 2015;106(2):194-205. https://doi.org/10.1093/cvr/cvv105
23. Chilton R, Tikkanen I, Cannon CP, et al. Effects of empagliflozin on blood pressure and markers of arterial stiffness and vascular resistance in patients with type 2 diabetes. Diabetes Obes Metab. 2015;17(12):1180-1193. https://doi.org/10.1111/dom.12572
24. Tikkanen I, Narko K, Zeller C, et al. Empagliflozin reduces blood pressure in patients with type 2 diabetes and hypertension. Diabetes Care. 2015;38(3):420-428. https://doi.org/10.2337/dc14-1096
25. Kusaka H, Koibuchi N, Hasegawa Y, Ogawa H, Kim-Mitsuyama S. Empagliflozin lessened cardiac injury and reduced visceral adipocyte hypertrophy in prediabetic rats with metabolic syndrome. Cardiovasc Diabetol. 2016;15(1):157. https://doi.org/10.1186/s12933-016-0473-7
26. Hammoudi N, Jeong D, Singh R, et al. Empagliflozin improves left ventricular diastolic dysfunction in a genetic model of type 2 diabetes. Cardiovasc Drugs Ther. 2017;31(3):233-246. https://doi.org/10.1007/s10557-017-6734-1
27. Habibi J, Aroor AR, Sowers JR, et al. Sodium glucose transporter 2 (SGLT2) inhibition with empagliflozin improves cardiac diastolic function in a female rodent model of diabetes. Cardiovasc Diabetol. 2017;16(1):9. https://doi.org/10.1186/s12933-016-0489-z
28. Verma S, Garg A, Yan AT, et al. Effect of empagliflozin on left ventricular mass and diastolic function in individuals with diabetes: an important clue to the EMPA-REG OUTCOME trial? Diabetes Care. 2016;39(12):e212 LP-e213
29. Andreadou I, Efentakis P, Balafas E, et al. Empagliflozin limits myocardial infarction in vivo and cell death in vitro: role of STAT3, mitochondria, and redox aspects. Front Physiol. 2017;8:1077
30. Zhong M, Alonso CE, Taegtmeyer H, Kundu BK. Quantitative PET imaging detects early metabolic remodeling in a mouse model of pressure-overload left ventricular hypertrophy in vivo. J Nucl Med. 2013;54(4):609-615. https://doi.org/10.2967/jnumed.112.108092
31. Heyen JRR, Blasi ER, Nikula K, et al. Structural, functional, and molecular characterization of the SHHF model of heart failure. Am J Physiol Heart Circ Physiol. 2002;283(5):H1775-H1784. https://doi.org/10.1152/ajpheart.00305.2002
32. Youcef G, Olivier A, L'Huillier CPJ, et al. Simultaneous characterization of metabolic, cardiac, vascular and renal phenotypes of lean and obese SHHF rats. PLoS One. 2014;9(5):e96452. https://doi.org/10.1371/journal.pone.0096452